Terug
9
17
Dagbereik
€ 11,37
€ 11,57
52-Weeksbereik
€ 7,67
€ 12,84
Volume
438.220
50D / 200D Gem.
€ 11,63
/
€ 11,51
Vorige Slotkoers
€ 11,49
Koershistorie
Financiële Trends
Sectorvergelijking
vs Financial Services sector mediaan (854 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 1,6 | 10,3 |
| P/B | 0,1 | 1,1 |
| ROE % | 4,7 | 11,6 |
| Net Margin % | 18,3 | 16,8 |
| Rev Growth 5Y % | -5,8 | 11,6 |
| D/E | 0,0 | 0,5 |
Koersdoel Analisten
Hold
€ 10,00
-12.7%
Forward K/W
1,1
Forward WPA
€ 10,87
WPA Groei (sch.)
+0,0%
Omzet Sch.
2,7 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 11,75
€ 11,41 – € 12,11
|
2,9 B | 1 |
| FY2026 |
€ 10,87
€ 10,55 – € 11,20
|
2,7 B | 2 |
Insider Trading Activity
Buy ratio (90d)
0.0%
19 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 18, 2026 |
Berkowitz Noah
Chief Medical Officer
|
sell | 6.435 | € 11,10 | € 71.431 |
| Mar 16, 2026 |
MacGregor Bannor Michael
CEO
|
sell | 500.000 | € 0,05 | € 25.000 |
| Feb 26, 2026 |
Berkowitz Noah
Chief Medical Officer
|
grant | 112.000 | — | — |
| Feb 17, 2026 |
Stayton Noah Edward
EVP, Chief Information Officer
|
grant | 2.935 | — | — |
| Feb 13, 2026 |
Berkowitz Noah
Chief Medical Officer
|
sell | 5.685 | € 11,89 | € 67.595 |
| Jan 23, 2026 |
Clauser Noah
Chief Financial Officer
|
sell | 317.500 | — | — |
| Jan 2, 2026 |
Glass Noah H.
Director
|
grant | 26.143 | — | — |
| Dec 29, 2025 |
MacGregor Bannor Michael
CEO
|
sell | 1.768.555 | € 0,10 | € 232.830 |
| Oct 23, 2025 |
Popp Noah Nathaniel
EVP, GC and Secretary
|
grant | 3.240 | — | — |
| Sep 15, 2025 |
Popp Noah Nathaniel
EVP, GC and Secretary
|
grant | 2.589 | € 42,49 | € 110.007 |
| Aug 21, 2025 |
Stayton Noah Edward
EVP, Chief Information Officer
|
grant | 11.078 | — | — |
| Jun 19, 2025 |
Elbogen Noah A.
|
grant | 2.747 | € 45,52 | € 125.043 |
| Jun 10, 2025 |
Beren Noah
Director
|
grant | 2.985 | — | — |
| May 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 1.855 | € 10,50 | € 19.478 |
| May 9, 2025 |
Berkowitz Noah
Chief Medical Officer
|
grant | 150.600 | — | — |
| Apr 15, 2025 |
Glass Noah H.
Director
|
grant | 9.933 | — | — |
| Mar 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 1.911 | — | — |
| Mar 31, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
grant | 25.000 | — | — |
| Mar 29, 2025 |
BRODSKY NOAH
Chief Commercial Officer
|
other | 2.017 | — | — |
Belangrijkste Punten
Revenue declined -5,82% annually over 5 years
Earnings declined -52,90% over the past year
ROE of 4,69% is below average
Net margin of 18,28% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 305,16M in free cash flow
Groei
Revenue Growth (5Y)
-5,82%
Revenue (1Y)-21,06%
Earnings (1Y)-52,90%
FCF Growth (3Y)-26,84%
Kwaliteit
Return on Equity
4,69%
ROIC4,72%
Net Margin18,28%
Op. Margin24,37%
Veiligheid
Debt / Equity
0,01
Current Ratio4,53
Interest Coverage0,00
Waardering
P/E Ratio
1,61
P/B Ratio0,08
EV/EBITDA-4,61
Dividend Yield0,84%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -21,06% | Revenue Growth (3Y) | -8,41% |
| Earnings Growth (1Y) | -52,90% | Earnings Growth (3Y) | -30,23% |
| Revenue Growth (5Y) | -5,82% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2,60B | Net Income (TTM) | 475,45M |
| ROE | 4,69% | ROA | 4,04% |
| Gross Margin | 48,12% | Operating Margin | 24,37% |
| Net Margin | 18,28% | Free Cash Flow (TTM) | 305,16M |
| ROIC | 4,72% | FCF Growth (3Y) | -26,84% |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 4,53 |
| Interest Coverage | 0,00 | Dividend Yield | 0,84% |
| Valuation | |||
| P/E Ratio | 1,61 | P/B Ratio | 0,08 |
| P/S Ratio | 0,29 | PEG Ratio | -0,05 |
| EV/EBITDA | -4,61 | Dividend Yield | 0,84% |
| Market Cap | 764,27M | Enterprise Value | -2,92B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 2,60B | 3,29B | 3,10B | 4,29B | 3,31B |
| Net Income | 475,45M | 1,01B | 976,57M | 1,31B | -745,23M |
| EPS (Diluted) | 33,75 | 72,65 | 71,40 | 97,25 | -60,05 |
| Gross Profit | 1,25B | 1,84B | 1,66B | 2,12B | 2,61B |
| Operating Income | 633,89M | 1,10B | 1,09B | 1,20B | 1,26B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 11,78B | 12,69B | 11,80B | 10,89B | 9,40B |
| Total Liabilities | 1,77B | 2,26B | 2,30B | 2,75B | 2,12B |
| Shareholders' Equity | 9,95B | 10,31B | 9,41B | 8,04B | 7,19B |
| Total Debt | 135,99M | 327,06M | 177,99M | 222,24M | 280,86M |
| Cash & Equivalents | 3,82B | 5,19B | 4,40B | 3,40B | 5,01B |
| Current Assets | 6,47B | 7,12B | 6,32B | 5,52B | 6,70B |
| Current Liabilities | 1,43B | 1,89B | 1,90B | 2,28B | 1,88B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#802 of 825
#504 of 710
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026